DYAI

Dyadic International, Inc. (DYAI) | Rumor.io

Dyadic International

DYAI

Attention (50-day avg)0%

Attention rank (50-day avg)#4,012

Bullish sentiment (50-day avg)0%

Price to earnings ratio-2.04

Market capitalization18.8M

Earnings per share-0.21

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-7.4M

Social

What share of all stock conversation is about DYAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 21

The company has announced a $10M contract, and the author estimates they will earn $1/share, potentially leading to hyperbolic stock growth above $25/share.
The author has set a target price of $2 for DYAI stock and vows not to exit the position until it's reached.
The author believes DYAI has a clear path ahead, with the potential for the stock to gap above $2/share this week.

Generated by AI

Sentiment

Of the messages about DYAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.58% +5.06
Bearish	—	—	—	12.42% -5.06

Bullish· Aug 25

$DYAI has shown significant price appreciation, with a 20% increase for the day and a new high reached.
The asset's chart is showing signs of reversal and potential continued growth, with a possible target price of $6.
$DYAI's strong performance is not an isolated event, as it is part of a group of tickers that are experiencing similar chart patterns and potential for growth.

Bearish· May 28

The asset's price has declined significantly, with one user down $375 and another down $770.
The company's cash runway is limited, with one user mentioning that the asset will run out of cash until Q2 2027.
The asset's volume has decreased, with one user stating that volume "went to shit".

Generated by AI

Topics

Of the messages about DYAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	98.07%
Technical Analysis	—	—	—	1.19%
Earnings	—	—	—	0.44%
Analysts	—	—	—	0.3%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Announcements· Jun 11

Dyadic International, Inc. ($DYAI) collaborates with Scripps Research on rapid-response hantavirus antibody and vaccine development.
The partnership aims to evaluate hantavirus antibody/vaccine candidates, leveraging Dyadic's scalable microbial protein platforms.
Dyadic International is gaining traction in the biotech sector, with its collaboration with Scripps Research on hantavirus antibodies/vaccines seen as a potential catalyst for growth.

Technical Analysis· Aug 16

$DYAI is showing potential breakouts over the 5.25/5.20 level, with a float of 9 million and volume of 5 million so far.
The stock has a big pivot to reclaim, with a key break at 5.15 and a held level at 4 nicely, indicating a possible continuation with initial breakout and low volume consolidation near the 9EMA.
$DYAI is in an uptrend, with a prevailing flag and 3 strong support points, suggesting an "uptrend coming" and a potential move towards the 6.90 area.

Generated by AI

Community

Of the messages about DYAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	75%	43.87%
Newcomers	—	0%	25%	56.13%

Regulars· Jun 11

Dyadic International's collaboration with Scripps Research on hantavirus antibody and vaccine development is gaining traction, highlighting the company's scalable microbial protein platforms.
The focus on manufacturing capabilities, such as process adaptability for seamless scale-up, is crucial for the adoption of biologics technologies, making Dyadic International an important read for biotech investors.
Dyadic International's work in engineering the global future of protein production, leveraging Moores law for biomanufacturing, is a key factor in the company's growth and potential for future success.

Newcomers· Jun 6

New investors are drawn to DYAI due to its potential as a bird flu stock, comparing it to other companies in the same space.
The stock's volume and price movement are being closely watched, with some speculating that it could be the "monster play" that hasn't moved yet.
A focus is on the company's vaccine and pharmaceutical capabilities, with some investors considering it a potential catalyst for the bird flu market.

Generated by AI

News

Dyadic International (Nasdaq: DYAI) Advances Protein Manufacturing Platforms with Global Health Research Support

Support from global health organizations highlights continued development of Dyadic’s C1 and Dapibus platforms for

29d agoUSA Today

Imperium AI Announces Board Discussion Regarding Dyadic Biotechnology Developments

Imperium AI Founder and CEO Shazir Mucklai will lead an internal review of Dyadic’s biotechnology platforms,

29d agoUSA Today

Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing With Global Health Support to Help Turn AI-Designed DNA Into Life-Saving Products

29d agoBarchart.com

Imperium AI CEO Shazir Mucklai on Major Potential in Dyadic (NASDAQ: DYAI), Calls Board Meeting to Discuss Next Steps

29d agoBarchart.com

Dyadic Applied BioSolutions at q3 investor summit group virtual conference 2026: push to cash flow By Investing.com

1mo agoInvesting.com

Dyadic International (DYAI) Q2 2026 Earnings Call Transcript

Detailed price information for Dyadic International (DYAI-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about DYAI also mention

#	Name	Attention
1	WHLM - Wilhelmina International, Inc.	——
2	NanoVibronix, Inc.NAOV	0%0
3	CWBR - CohBar, Inc.	——
4	MediaCo Holding Inc. Class A Common StockMDIA	0%0
5	Flora Growth Corp.FLGC	0%new
6	American BriVision (Holding) CorporationABVC	0%+0
7	Lantern Pharma Inc.LTRN	0%+0
8	Xenetic Biosciences, Inc.XBIO	0%new
9	Good Times Restaurants Inc.GTIM	0%new
10	Ark Restaurants Corp.ARKR	0%0

Dyadic International, Inc.

Healthcare
Biotechnology

Dyadic International, Inc. is a biotechnology company focused on scalable protein production for non-pharmaceutical applications. Through its proprietary C1 and Dapibus expression platforms, Dyadic develops and commercializes precision-engineered proteins and enzymes used in life sciences, food and nutrition, and industrial biotechnology. Its technology is designed to support the efficient manufacture of recombinant, animal-free inputs that can be sold directly or licensed to partners across multiple markets. The company’s current business centers on producing functional proteins for customers seeking flexible, cost-effective biomanufacturing solutions in areas such as specialty ingredients, enzyme development, and other bioindustrial uses. Dyadic International, Inc. is headquartered in Jupiter, Florida, and operates as a global biotechnology platform company serving commercial and research-oriented applications.

Website

Location

1044 North U.S. Highway One

Jupiter, FL, 33477-5094

United States

Social

What share of all stock conversation is about DYAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Jul 21

The company has announced a $10M contract, and the author estimates they will earn $1/share, potentially leading to hyperbolic stock growth above $25/share.
The author has set a target price of $2 for DYAI stock and vows not to exit the position until it's reached.
The author believes DYAI has a clear path ahead, with the potential for the stock to gap above $2/share this week.

Generated by AI

Sentiment

Of the messages about DYAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.58% +5.06
Bearish	—	—	—	12.42% -5.06

Bullish· Aug 25

$DYAI has shown significant price appreciation, with a 20% increase for the day and a new high reached.
The asset's chart is showing signs of reversal and potential continued growth, with a possible target price of $6.
$DYAI's strong performance is not an isolated event, as it is part of a group of tickers that are experiencing similar chart patterns and potential for growth.

Bearish· May 28

The asset's price has declined significantly, with one user down $375 and another down $770.
The company's cash runway is limited, with one user mentioning that the asset will run out of cash until Q2 2027.
The asset's volume has decreased, with one user stating that volume "went to shit".

Generated by AI

Topics

Of the messages about DYAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	98.07%
Technical Analysis	—	—	—	1.19%
Earnings	—	—	—	0.44%
Analysts	—	—	—	0.3%
Controversies	—	—	—	0%
Macro	—	—	—	0%

Announcements· Jun 11

Dyadic International, Inc. ($DYAI) collaborates with Scripps Research on rapid-response hantavirus antibody and vaccine development.
The partnership aims to evaluate hantavirus antibody/vaccine candidates, leveraging Dyadic's scalable microbial protein platforms.
Dyadic International is gaining traction in the biotech sector, with its collaboration with Scripps Research on hantavirus antibodies/vaccines seen as a potential catalyst for growth.

Technical Analysis· Aug 16

$DYAI is showing potential breakouts over the 5.25/5.20 level, with a float of 9 million and volume of 5 million so far.
The stock has a big pivot to reclaim, with a key break at 5.15 and a held level at 4 nicely, indicating a possible continuation with initial breakout and low volume consolidation near the 9EMA.
$DYAI is in an uptrend, with a prevailing flag and 3 strong support points, suggesting an "uptrend coming" and a potential move towards the 6.90 area.

Generated by AI

Community

Of the messages about DYAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	75%	43.87%
Newcomers	—	0%	25%	56.13%

Regulars· Jun 11

Dyadic International's collaboration with Scripps Research on hantavirus antibody and vaccine development is gaining traction, highlighting the company's scalable microbial protein platforms.
The focus on manufacturing capabilities, such as process adaptability for seamless scale-up, is crucial for the adoption of biologics technologies, making Dyadic International an important read for biotech investors.
Dyadic International's work in engineering the global future of protein production, leveraging Moores law for biomanufacturing, is a key factor in the company's growth and potential for future success.

Newcomers· Jun 6

New investors are drawn to DYAI due to its potential as a bird flu stock, comparing it to other companies in the same space.
The stock's volume and price movement are being closely watched, with some speculating that it could be the "monster play" that hasn't moved yet.
A focus is on the company's vaccine and pharmaceutical capabilities, with some investors considering it a potential catalyst for the bird flu market.

Generated by AI

Dyadic International

Social

Jul 21

Bullish· Aug 25

Bearish· May 28

Announcements· Jun 11

Technical Analysis· Aug 16

Regulars· Jun 11

Newcomers· Jun 6

Dyadic International (Nasdaq: DYAI) Advances Protein Manufacturing Platforms with Global Health Research Support

Imperium AI Announces Board Discussion Regarding Dyadic Biotechnology Developments

Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing With Global Health Support to Help Turn AI-Designed DNA Into Life-Saving Products

Imperium AI CEO Shazir Mucklai on Major Potential in Dyadic (NASDAQ: DYAI), Calls Board Meeting to Discuss Next Steps

Dyadic Applied BioSolutions at q3 investor summit group virtual conference 2026: push to cash flow By Investing.com

Dyadic International (DYAI) Q2 2026 Earnings Call Transcript

Also Discussed

Dyadic International, Inc.

Company Information

Location

Dyadic International (Nasdaq: DYAI) Advances Protein Manufacturing Platforms with Global Health Research Support

Imperium AI Announces Board Discussion Regarding Dyadic Biotechnology Developments

Dyadic International (Nasdaq: DYAI) Advances Next-Generation Biomanufacturing With Global Health Support to Help Turn AI-Designed DNA Into Life-Saving Products

Imperium AI CEO Shazir Mucklai on Major Potential in Dyadic (NASDAQ: DYAI), Calls Board Meeting to Discuss Next Steps

Dyadic Applied BioSolutions at q3 investor summit group virtual conference 2026: push to cash flow By Investing.com

Dyadic International (DYAI) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Jul 21

Bullish· Aug 25

Bearish· May 28

Announcements· Jun 11

Technical Analysis· Aug 16

Regulars· Jun 11

Newcomers· Jun 6